American Cancer Society recommends biennial prostate cancer screening for average-risk men
Solo los hechos

American Cancer Society recommends biennial prostate cancer screening for average-risk men

Resumen

The American Cancer Society updated its guidelines to advise men aged 50 and older to undergo PSA testing every two years, with earlier annual screening for Black men and those with a strong family history.

The American Cancer Society has revised its prostate-cancer screening recommendations, calling for men at average risk to receive a PSA test every two years beginning at age 50. The guideline adds that Black men and those with a strong family history should be screened annually starting at age 45.

The change, published in CA: A Cancer Journal for Clinicians, reflects new evidence that regular PSA testing reduces mortality from prostate cancer. Dr. William Dahut, chief scientific officer of the Society, said the recommendation aims to encourage men to consider screening and noted that after age 70 the decision returns to an individual basis.

Experts highlighted that earlier guidelines emphasized shared decision-making, but the Society believes a clear recommendation will increase testing rates. Dr. Neeraj Agarwal, an oncologist at Dana-Farber Cancer Institute, said many men were not offered the test under the previous approach.

Prostate-specific antigen (PSA) testing measures the level of a protein produced by the prostate. An abnormal result is defined as 3 ng/mL or higher for men 69 and younger, and 6.5 ng/mL or higher for men 70-74. Dr. Yaw Nyame, who served on the expert panel, noted that an early baseline PSA can help tailor future screening.

Prostate cancer remains the second-leading cause of cancer death among U.S. men, with diagnoses rising about 3 % per year from 2014-2022. The Society estimates roughly one in eight men will be diagnosed during their lifetime, and early detection yields a five-year survival rate above 99 %.

The updated recommendation differs from the U.S. Preventive Services Task Force (USPSTF), which still advises individualized decision-making for men 55-69 and assigns a C grade to PSA screening. The USPSTF is reportedly reviewing its guidance.

Coverage for PSA testing is generally provided by Medicare and many private insurers, but follow-up procedures such as MRI, biomarker tests, and biopsies often incur out-of-pocket costs. Dr. Agarwal said a formal recommendation may help insurers and policymakers align coverage with the full diagnostic pathway.

Experts emphasized that while PSA testing is not perfect and can produce false-positive results, it remains an effective tool for reducing prostate-cancer deaths, especially when combined with newer imaging and biomarker technologies.

The guideline also underscores higher risk among Black men, who develop prostate cancer earlier and have higher mortality rates. Some specialists suggest screening for Black men could begin as early as age 40. Legislative proposals, such as the PSA Screening for HIM Act, aim to expand insurance coverage for high-risk groups.

Overall, the Society’s updated guidance seeks to simplify screening decisions for primary-care providers and improve early detection rates across the United States.

Fuente

CNN

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.